News Sentiment

CAPR sentiment intelligence

Capricor Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.44 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.6% over one week, -31.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -9.6% Price reacting lower
Trend fit Trend inactive -31.5% over four weeks
Fair value 59.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 8
Stocktwits 7
Stock Titan 6
Simply Wall Street 3
Moomoo 3
Sahm 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 15
Regulatory and legal 8
Analyst action 5
Guidance 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
MarketBeat Direct company coverage

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) shares recently fell below their 200-day moving average, trading as low as $18.98, significantly under the $27.65 average. Despite this, analyst sentiment remains largely positive with a consensus "Moderate Buy" rating and an average price targ

Tone
Negative 40/100
Event
Analyst action
Published
22 Jul 2026 07:39
Source
MarketBeat
Simply Wall Street Direct company coverage

Can Capricor Therapeutics’ (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility?

Capricor Therapeutics has leased a new 171,000 sq ft headquarters in San Diego, contingent on FDA approval of its drug Deramiocel for Duchenne muscular dystrophy by December 31, 2026. This significant expansion directly ties the company's future facilities to a critical regulator

Tone
Positive 63/100
Event
Regulatory and legal
Published
18 Jul 2026 18:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA Approval

Capricor Therapeutics has signed a major headquarters relocation and expansion lease directly linked to the potential FDA approval of its lead therapy, Deramiocel, for Duchenne muscular dystrophy. This strategic move aligns Capricor's future operational growth, including expanded

Tone
Neutral 50/100
Event
Regulatory and legal
Published
17 Jul 2026 06:11
Source
Simply Wall Street
TradingView Direct company coverage

ETFs Investing in Capricor Therapeutics, Inc. Stocks

This article lists various ETFs that include Capricor Therapeutics, Inc. (4LN2) stocks in their portfolios. It provides a detailed table outlining each ETF's market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 04:40
Source
TradingView
Investing.com Direct company coverage

Cantor Fitzgerald reiterates Overweight on Capricor stock at $62

Cantor Fitzgerald has reiterated an Overweight rating and a $62.00 price target for Capricor Therapeutics (NASDAQ:CAPR). The firm anticipates FDA approval for deramiocel, a Duchenne muscular dystrophy treatment, following its August 22 PDUFA date and plans to discuss early launch

Tone
Positive 65/100
Event
Analyst action
Published
15 Jul 2026 13:40
Source
Investing.com
Stock Titan Direct company coverage

Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease

Capricor Therapeutics (NASDAQ: CAPR) has signed a long-term lease for a new 171,000 sq ft headquarters in San Diego, which will include expanded manufacturing cleanrooms and R&D labs. The lease commencement is contingent on FDA approval of its drug Deramiocel for Duchenne muscula

Tone
Positive 64/100
Event
Regulatory and legal
Published
14 Jul 2026 20:49
Source
Stock Titan
MarketBeat Direct company coverage

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving Average - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) shares recently traded below their 200-day moving average, reaching $20.17 compared to the average of $28.05. Despite this, analysts maintain a "Moderate Buy" rating with a consensus price target of $53.67. The company also reported a wider-tha

Tone
Negative 30/100
Event
Analyst action
Published
14 Jul 2026 07:40
Source
MarketBeat
Stock Traders Daily Direct company coverage

Behavioral Patterns of CAPR and Institutional Flows

This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR), highlighting a weak near- and mid-term sentiment that contrasts with a positive long-term outlook. AI-generated trading strategies are provided for position trading, momentum breakout, and risk hedging. The analysis

Tone
Negative 39/100
Event
Guidance
Published
13 Jul 2026 04:12
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough

Capricor Therapeutics (CAPR) is highlighted as a pioneer in exosome technology, particularly with its lead drug Deramiocel targeting Duchenne Muscular Dystrophy (DMD). The article emphasizes the strong clinical trial results for Deramiocel, especially concerning cardiac function

Tone
Positive 78/100
Event
Earnings
Published
12 Jul 2026 14:12
Source
Simply Wall Street
Moomoo Direct company coverage

Capricor Therapeutics Company Profile & Introduction

This article provides a company profile and introduction to Capricor Therapeutics. It details the company's business activities, potentially including its therapeutic areas, pipeline, and strategic focus.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 13:16
Source
Moomoo
The Globe and Mail Direct company coverage

Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Capricor Therapeutics (CAPR) with a price target of $62.00. This rating aligns with a "Strong Buy" consensus from analysts, projecting a 136.29% upside. However, the company reported an increased GAAP net loss of

Tone
Positive 76/100
Event
Analyst action
Published
09 Jul 2026 01:09
Source
The Globe and Mail
Sahm Direct company coverage

Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit News - Has The Bull Case Changed?

Capricor Therapeutics (CAPR) saw its stock drop 5.8% following news of an upcoming FDA advisory committee review for its Duchenne muscular dystrophy therapy, Deramiocel, and its removal from several Russell indexes. Despite positive long-term data for Deramiocel and an FDA review

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 22:38
Source
Sahm
Sahm Direct company coverage

Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus

Capricor Therapeutics (CAPR) has seen a significant 442% return over the past three years, but current market multiples suggest the stock is overvalued. While its price-to-book ratio is higher than the biotech sector average, it is slightly below its peer group, leading to a mixe

Tone
Negative 37/100
Event
Market update
Published
05 Jul 2026 12:11
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBITDA forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR

This article provides the enterprise value to EBITDA forward for Capricor Therapeutics, Inc. (NASDAQ: CAPR) as presented on TradingView. It includes basic company information and navigational links typical of a financial data platform.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 23:39
Source
TradingView
Moomoo Direct company coverage

Capricor Therapeutics (NASDAQ:CAPR) Is In A Strong Position To Grow Its Business

This article analyzes Capricor Therapeutics (NASDAQ:CAPR), asserting that it is well-positioned for business growth. The analysis likely delves into the company's financials, pipeline, and market position to support this optimistic outlook.

Tone
Positive 77/100
Event
Guidance
Published
04 Jul 2026 13:10
Source
Moomoo
GuruFocus Direct company coverage

Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript

This earnings call transcript summarizes Capricor Therapeutics Inc.'s Q4 2025 financial results and clinical developments. Key positive points include FDA acceptance of their BLA for Jeremiasel (targeting August 2026 action), promising HOPE 3 trial results for Duchenne muscular d

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 12:10
Source
GuruFocus
TradingView Direct company coverage

Enterprise value to revenue forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR

This article displays the "Enterprise value to revenue forward" for Capricor Therapeutics, Inc. (NASDAQ: CAPR) on TradingView. It indicates that the market was closed at the time of viewing, with no trades observed. The content provides basic financial information access for the

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR

The article mentions the "Price to sales forward" metric for Capricor Therapeutics, Inc. (NASDAQ: CAPR). It appears to be a financial data point available on TradingView, within the company's financial overview. The content provided is minimal, focusing on navigation and data att

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 02:10
Source
TradingView
Sahm Direct company coverage

Capricor Therapeutics (CAPR) Could Be 58% Undervalued Following FDA Focus And Index Removal

Capricor Therapeutics (CAPR) shares have experienced significant short-term pressure due to removal from Russell indices and upcoming FDA advisory committee discussions on its Duchenne muscular dystrophy therapy, Deramiocel. Despite this, the company's long-term returns remain st

Tone
Positive 66/100
Event
Market update
Published
03 Jul 2026 23:40
Source
Sahm
Finviz Direct company coverage

CAPR - Capricor Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Capricor Therapeutics Inc (CAPR), including its stock performance, key financial metrics, and volatility. It covers data such as market capitalization, income, sales, insider and institutional ownership, and various performan

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 13:10
Source
Finviz
The National Law Review Direct company coverage

Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR) - Recover Losses - Contact Levi & Korsinsky Before September 15, 2025

A class action lawsuit has been filed against Capricor Therapeutics, Inc. (CAPR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between October 9, 2024, and July 10, 2025. The lawsuit alleges securities fraud, claiming Capricor made misle

Tone
Negative 29/100
Event
Regulatory and legal
Published
01 Jul 2026 10:40
Source
The National Law Review
TradingView Direct company coverage

Capricor Therapeutics, Inc. Financial Disclosures & Filings

This page provides a comprehensive list of Capricor Therapeutics, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategy. Key documents include earnings reports, corporate presentations, and updates on the progress of th

Tone
Positive 73/100
Event
Earnings
Published
01 Jul 2026 00:41
Source
TradingView
Market source Direct company coverage

CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review

Capricor Therapeutics (CAPR) shares recently hit a four-month low following news that two senior executives sold nearly $1.5 million in shares. This comes as the company prepares for a critical FDA review of its Duchenne muscular dystrophy treatment, Deramiocel, with an advisory

Tone
Neutral 50/100
Event
Balance sheet
Published
30 Jun 2026 12:15
Source
Market source
Investing.com Nigeria Direct company coverage

Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Capricor Therapeutics Inc. The filing date is June 29, and the article was published on June 30, 2026. The content includes market data for various indices, commodities, and shares, indicatin

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 02:39
Source
Investing.com Nigeria